# Natera, Inc. (NTRA) Stock Analysis: Understanding the 19.44% Upside Potential and Analyst Confidence

- Link: https://www.directorstalkinterviews.com/natera-inc-ntra-stock-analysis-understanding-the-19-44-upside-potential-and-analyst-confidence/4121213430
- Published: 2025-08-25T10:19:29+01:00
- Author: Madison Wilson

Natera, Inc. (NTRA), a key player in the healthcare sector specializing in diagnostics
and research, is garnering significant attention from investors. With a market capitalization
of $22.73 billion, the Austin, Texas-based company is known for its molecular testing
services, including a suite of innovative products that span prenatal testing, cancer
screening, and transplant diagnostics.

Currently trading at $165.60, Natera’s stock has experienced a slight price change
of 0.02%, maintaining a stable position within its 52-week range of $112.90 to $
177.00. The stock exhibits a resilient outlook as suggested by its technical indicators,
with a 50-day moving average of $154.80 and a 200-day moving average of $156.72,
alongside a Relative Strength Index (RSI) of 64.88, indicating a bullish momentum.

A standout aspect of Natera’s financials is its impressive revenue growth of 32.20%,
a figure that underscores the company’s robust business expansion and market penetration
capabilities. However, the company faces challenges on the profitability front, 
with an EPS of -1.90 and a return on equity of -24.32%, indicative of ongoing investments
in growth and development that have yet to yield positive income.

The company’s valuation metrics reveal an intriguing scenario for investors. The
forward P/E ratio stands at -182.63, reflecting the market’s expectations for future
earnings growth despite current losses. This is further highlighted by the absence
of traditional valuation figures such as PEG ratio, price/book, and price/sales,
often characteristic of high-growth tech and biotech firms in their expansion phase.

Natera does not currently offer a dividend, aligning with its strategy of reinvestment
into research and development to further its product portfolio, which includes the
Panorama non-invasive prenatal test, the Signatera molecular residual disease test,
and other groundbreaking diagnostics.

Investor sentiment towards Natera is overwhelmingly positive, with 19 buy ratings
against a single sell rating, and no hold ratings. Analysts have set a broad target
price range from $37.00 to $255.00, with an average target price of $197.80. This
suggests a potential upside of 19.44%, a factor that could make Natera an attractive
option for growth-focused investors.

Moreover, Natera’s strategic partnerships with BGI Genomics Co., Ltd. and Foundation
Medicine, Inc. highlight its commitment to advancing genetic testing technologies
and expanding its market reach. These alliances, combined with its innovative product
lineup, position Natera well in the competitive landscape of molecular diagnostics.

For investors, Natera represents a compelling growth story within the healthcare
diagnostics space. While challenges remain, especially in achieving profitability,
the company’s strong revenue growth, innovative product offerings, and positive 
analyst outlook suggest that Natera is a stock to watch for those willing to embrace
the potential risks and rewards of investing in a high-growth, high-impact sector.

Share on:
